Discuss $Regencell Bioscience(RGC.US) from a technical and risk perspective. Although this stock now sees daily fluctuations of 10% or 20%, its fundamentals are weak: annual reports show zero revenue in recent years with significant net losses. The company admits it may never turn a profit, and its going concern is uncertain. Such high valuations require a very solid future narrative, but even the core technology's FDA clinical results remain unverified. Money purely driven by rumors is truly not something to hold long-term.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
